EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor Intrinsic Immunogenicity Suppressor SETDB1 Worsens the Prognosis of Patients with Hepatocellular Carcinoma

Chang-Qing Yin iD, Chun-Qing Song

Cells · 2024

DOI: 10.3390/cells13242102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Chang-Qing Yin und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Zhejiang University, Hangzhou 310058, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Histone-Lysine N-Methyltransferase, Liver Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, Westlake Laboratory of Life Sciences and Biomedicine HRHI program, Westlake Education Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is clinically distinguished by its covert onset, rapid progression, high recurrence rate, and poor prognosis. Studies have revealed that SETDB1 (SET Domain Bifurcated 1) is a histone H3 methyltransferase located on chromosome 1 and plays a crucial role in carcinogenesis. Therefore, we aimed to evaluate the clinical significance of SETDB1 expression in HCC. In patients with HCC, elevated levels of SETDB1 correlated with a poorer overall survival (OS) rate, marking it as an independent prognostic factor for HCC, as revealed by both univariate and multivariate Cox analyses. Furthermore, we utilized the SangerBox and TISIDB databases to profile the tumor immune microenvironment in HCC, including scoring the tumor microenvironment and assessing immune cell infiltration. The TIDE algorithm was employed to examine the association between SETDB1 expression and immune responses. Our findings indicated that SETDB1 expression negatively correlated with the majority of immune cells, a wide range of immune cell marker genes, and numerous immune pathways, thereby leading to the reduced effectiveness of immune checkpoint inhibitors. Lastly, both in vivo and ex vivo experiments were conducted to substantiate the role of SETDB1 in HCC tumorigenesis. In conclusion, the upregulation of SETDB1 is associated with a poorer prognosis in HCC patients and inversely correlates with immune cell infiltration, potentially serving as a predictive marker for immunotherapy response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularHistone-Lysine N-MethyltransferaseLiver NeoplasmsHumansPrognosisFemaleMaleTumor MicroenvironmentAnimalsGene Expression Regulation, NeoplasticMiddle AgedCell Line, TumorMiceBiomarkers, Tumor

Stichwörter der Autor:innen

SETDB1hepatocellular carcinomaimmune cell infiltrationprognosis

Substanzen

Histone-Lysine N-MethyltransferaseSETDB1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • College of Life Sciences, Zhejiang University, Hangzhou 310058, China.
  • Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China.
  • Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China.
  • Laboratory of Gene Therapeutic Biology, Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou 310024, China.

ORCID-Profile: Chang-Qing Yin

Förderung

  • the National Natural Science Foundation of China
  • Westlake Laboratory of Life Sciences and Biomedicine HRHI program
  • Westlake Education Foundation

Zitieren

APA

Yin, C. Q., & Song, C. Q. (2024). Tumor Intrinsic Immunogenicity Suppressor SETDB1 Worsens the Prognosis of Patients with Hepatocellular Carcinoma. Cells. https://doi.org/10.3390/cells13242102

Vancouver

Yin CQ, Song CQ. Tumor Intrinsic Immunogenicity Suppressor SETDB1 Worsens the Prognosis of Patients with Hepatocellular Carcinoma. Cells. 2024. doi:10.3390/cells13242102

BibTeX
@article{Yin2024,
  author = {Yin, Chang-Qing and Song, Chun-Qing},
  title = {Tumor Intrinsic Immunogenicity Suppressor SETDB1 Worsens the Prognosis of Patients with Hepatocellular Carcinoma},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13242102}
}
Kostenlos starten →